|Bid||120.05 x 1100|
|Ask||121.16 x 1000|
|Day's range||114.02 - 120.18|
|52-week range||72.67 - 134.84|
|Beta (5Y monthly)||1.41|
|PE ratio (TTM)||11.32|
|Earnings date||22 Jul 2020 - 27 Jul 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||139.45|
Alexion (ALXN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
The stock market continued to gain ground at midday on Thursday, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) participated in the modest rally. Slightly before noon EDT, the index was up just over half a percent, as was the Nasdaq 100 Index of top stocks on the exchange. Workday (NASDAQ: WDAY) and Alexion Pharmaceuticals (NASDAQ: ALXN) rose for different reasons, but their gains were among the leaders in the Nasdaq 100 and showed the broad-based support that the rally has had recently.
Alexion Announces Upcoming Data Presentations at the Virtual 25th Congress of the European Hematology Association
"The best approach for the Company and its stakeholders is the immediate exploration of a sale," Elliott Associates said in the letter, made public one day before Alexion's annual shareholder meeting. Rather than consider a sale, Alexion has been on an acquisition spree, seeking to diversify its research pipeline, deals the hedge fund criticized in the letter. Elliott said it had waited months for CEO Ludwig Hantson's "go-it-alone" approach to gain traction and is speaking out now after he announced plans to buy Portola Pharmaceuticals Inc. Alexion shares tumbled on the announcement last week, erasing approximately $1.7 billion from the company's market capitalization in one day.
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q1 earnings releases amid the coronavirus crisis.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
If other factors are constant while comparing stocks, the one with a higher earnings yield has the potential to provide comparatively greater returns.
Alexion (ALXN) delivered earnings and revenue surprises of 19.26% and 6.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Alexion to Present at the Virtual Bank of America Securities 2020 Healthcare Conference on Tuesday, May 12th
Shares of Portola Pharmaceuticals (NASDAQ: PTLA) -- a biopharmaceutical company that focuses on the development of treatments for life-threatening blood disorders -- are up by a whopping 129% as of 12:11 p.m. EDT on Tuesday. The company's shares more than doubled following the news that Portola reached an agreement to be acquired by Alexion Pharmaceuticals (NASDAQ: ALXN). Alexion will launch a tender offer to acquire all the outstanding shares of Portola for $18 per share in cash.
Alexion, which has been fighting to maintain its leadership in treating certain rare blood disorders, has embarked on a string of acquisitions to boost its pipeline of rare disease drugs. The acquisition will diversify Alexion's treatment portfolio beyond drugs targeting the C5 protein, which makes up part of the immune system that can sometimes attack the body's own healthy cells. Alexion will pay $18 per Portola share in cash, a premium of 132% to Portola's last closing price, the companies said.
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex Pharmaceuticals (NASDAQ: VRTX) and Alexion Pharmaceuticals (NASDAQ: ALXN) have each figured out the same winning strategy. Vertex has achieved greater success in recent years, though. Which biotech stock is the better pick now for long-term investors?
Alexion Receives CHMP Positive Opinion for ULTOMIRIS® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS).
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abeona's (ABEO) operating expenses are expected to have increased in the first quarter driven by clinical studies on its lead gene therapy candidate.